| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
The Journal of Immunology, Vol 156, Issue 3 1095-1100, Copyright © 1996 by American Association of Immunologists
ARTICLES |
F Fallarino, C Uyttenhove, T Boon and TF Gajewski
Ludwig Institute for Cancer Research, Catholic University of Louvain, Belgium.
Although murine tumor cells have been transfected to express a multitude of different cytokines and shown to be rejected in vivo, it is unclear which of these factors might be useful to facilitate tumor Ag immunization schemes. A study of the normal immune mechanisms involved in tumor rejection when it naturally occurs should reveal critical signals for generation of antitumor CTL in vivo. The highly transfectable variant of P815, P1.HTR, was found to be rejected in the hind footpads by approximately one-third of syngeneic DBA/2 mice. Analysis of draining popliteal lymph nodes revealed a large influx of CD4+ and CD8+ T lymphocytes in all mice, indicating that a failure to reject was not due to the complete absence of an inflammatory response. However, although IL-2 and IL-3 were produced by lymph node cells from all mice, only approximately one-third generated a high IFN-gamma response. IL-4 was not detected. To explore a role for IL-12 in the induction of the IFN-gamma-producing phenotype, a histidine-tagged IL- 12 fusion protein was expressed in mammalian cells and purified by nickel-chelate chromatography, and a rabbit antiserum was produced. Neutralization of IL-12 in vivo eliminated the high IFN-gamma response and prevented rejection of P1.HTR tumors and also of a more immunogenic tum- variant of P815, P198. Conversely, exogenous IL-12 delivered early during challenge with P1.HTR cells induced high IFN-gamma production and resulted in tumor rejection in most mice. Therefore, endogenous IL- 12 is vital for the rejection of these tumors when it naturally occurs, supporting a role for exogenous administration of this cytokine to favor a Th1-like phenotype in the immunotherapy of cancer.
This article has been cited by other articles:
|
|
 |
|
  P. W. Chen, T. Uno, and B. R. Ksander Tumor Escape Mutants Develop within an Immune-Privileged Environment in the Absence of T Cell Selection J. Immunol., July 1, 2006; 177(1): 162 - 168. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Nembrini, B. Abel, M. Kopf, and B. J. Marsland Strong TCR Signaling, TLR Ligands, and Cytokine Redundancies Ensure Robust Development of Type 1 Effector T Cells. J. Immunol., June 15, 2006; 176(12): 7180 - 7188. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A.D. Hauer, C. Uyttenhove, P. de Vos, V. Stroobant, J.C. Renauld, T.J.C. van Berkel, J. van Snick, and J. Kuiper Blockade of Interleukin-12 Function by Protein Vaccination Attenuates Atherosclerosis Circulation, August 16, 2005; 112(7): 1054 - 1062. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Ruiz-Ruiz, C. Ruiz de Almodovar, A. Rodriguez, G. Ortiz-Ferron, J. M. Redondo, and A. Lopez-Rivas The Up-regulation of Human Caspase-8 by Interferon-{gamma} in Breast Tumor Cells Requires the Induction and Action of the Transcription Factor Interferon Regulatory Factor-1 J. Biol. Chem., May 7, 2004; 279(19): 19712 - 19720. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Tschoep, T. C. Manning, H. Harlin, C. George, M. Johnson, and T. F. Gajewski Disparate functions of immature and mature human myeloid dendritic cells: implications for dendritic cell-based vaccines J. Leukoc. Biol., July 1, 2003; 74(1): 69 - 80. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. C. Peterson, H. Harlin, and T. F. Gajewski Immunization With Melan-A Peptide-Pulsed Peripheral Blood Mononuclear Cells Plus Recombinant Human Interleukin-12 Induces Clinical Activity and T-Cell Responses in Advanced Melanoma J. Clin. Oncol., June 15, 2003; 21(12): 2342 - 2348. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W. C. Kieper, M. Prlic, C. S. Schmidt, M. F. Mescher, and S. C. Jameson IL-12 Enhances CD8 T Cell Homeostatic Expansion J. Immunol., May 1, 2001; 166(9): 5515 - 5521. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. K. Kacha, F. Fallarino, M. A. Markiewicz, and T. F. Gajewski Spontaneous Rejection of Poorly Immunogenic P1.HTR Tumors by Stat6-Deficient Mice J. Immunol., December 1, 2000; 165(11): 6024 - 6028. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
U. Grohmann, J. Van Snick, F. Campanile, S. Silla, A. Giampietri, C. Vacca, J.-C. Renauld, M. C. Fioretti, and P. Puccetti IL-9 Protects Mice from Gram-Negative Bacterial Shock: Suppression of TNF-{alpha}, IL-12, and IFN-{gamma}, and Induction of IL-10 J. Immunol., April 15, 2000; 164(8): 4197 - 4203. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. Fallarino and T. F. Gajewski Cutting Edge: Differentiation of Antitumor CTL In Vivo Requires Host Expression of Stat1 J. Immunol., October 15, 1999; 163(8): 4109 - 4113. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. Mateo, J. Gardner, Q. Chen, C. Schmidt, M. Down, S. L. Elliott, S. J. Pye, H. Firat, F. A. Lemonnier, J. Cebon, et al. An HLA-A2 Polyepitope Vaccine for Melanoma Immunotherapy J. Immunol., October 1, 1999; 163(7): 4058 - 4063. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. S. Schmidt and M. F. Mescher Adjuvant Effect of IL-12: Conversion of Peptide Antigen Administration from Tolerizing to Immunizing for CD8+ T Cells In Vivo J. Immunol., September 1, 1999; 163(5): 2561 - 2567. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
